Trial Profile
A randomized, double-blind study comparing a fixed dose combination of telmisartan 40 mg plus hydrochlorothiazide 12.5 mg to telmisartan 40 mg in patients who fail to respond adequately to treatment with telmisartan 40 mg
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary) ; Telmisartan/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- 15 Nov 2007 Status changed from in progress to completed.
- 15 Nov 2005 New trial record.